Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Trial Profile

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Glioma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Oncoceutics
  • Most Recent Events

    • 06 Mar 2018 Status changed from recruiting to Completed.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top